## Adam Gater

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2194832/publications.pdf

Version: 2024-02-01

840776 677142 32 526 11 22 h-index citations g-index papers 33 33 33 785 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Qualitative evaluation of the symptoms and quality of life impacts of long-chain fatty acid oxidation disorders. Therapeutic Advances in Endocrinology and Metabolism, 2022, 13, 204201882110656.	3.2	1
2	Asthma Daytime Symptom Diary (ADSD) and Asthma Nighttime Symptom Diary (ANSD): Measurement Properties of Novel Patient-Reported Symptom Measures. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 1249-1259.	3.8	4
3	Patients' and clinicians' perspectives on item importance, scoring, and clinically meaningful differences for the Endometriosis Symptom Diary (ESD) and Endometriosis Impact Scale (EIS). Health and Quality of Life Outcomes, 2021, 19, 7.	2.4	2
4	Development and Content Validation of Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) in Adolescents and Adults with Moderate-to-Severe AD. Dermatology and Therapy, 2021, 11, 221-233.	3.0	12
5	Patient-Centered Insights on Treatment Decision Making and Living with Acute Myeloid Leukemia and Other Hematologic Cancers. Patient, 2020, 13, 83-102.	2.7	15
6	Development and First Use of the Patient's Qualitative Assessment of Treatment (PQAT) Questionnaire in Type 2 Diabetes Mellitus to Explore Individualised Benefit–Harm of Drugs Received During Clinical Studies. Drug Safety, 2020, 43, 119-134.	3.2	5
7	Evaluation of the Content Validity and Cross-Cultural Validity of the Study Participant Feedback Questionnaire (SPFQ). Therapeutic Innovation and Regulatory Science, 2020, 54, 1522-1533.	1.6	7
8	Understanding the Patient Experience of Severe, Recurrent, Bilateral Nasal Polyps: A Qualitative Interview Study in the United States and Germany. Value in Health, 2020, 23, 632-641.	0.3	11
9	Development and content validation of two new patient-reported outcome measures for endometriosis: the Endometriosis Symptom Diary (ESD) and Endometriosis Impact Scale (EIS). Journal of Patient-Reported Outcomes, 2020, 4, 13.	1.9	18
10	Fatigue, treatment satisfaction and health-related quality of life among patients receiving novel drugs suppressing androgen signalling for the treatment of metastatic castrate-resistant prostate cancer. European Journal of Cancer Care, 2019, 28, e12949.	1.5	11
11	The Potential Role of Individual-Level Benefit-Risk Assessment in Treatment Decision Making: A DIA Study Endpoints Community Workstream. Therapeutic Innovation and Regulatory Science, 2019, 53, 630-638.	1.6	11
12	Treatment Decision Making in AML: Factors of Importance to Clinicians, AML Patients and Their Family. Blood, 2019, 134, 3498-3498.	1.4	2
13	Preliminary Exploration of Patient Perspectives on Tyrosine Kinase Inhibitors for the Treatment of Chronic-Phase Chronic Myeloid Leukemia. Blood, 2019, 134, 5918-5918.	1.4	O
14	Qualitative and Quantitative Assessment of Patient and Carer Experience of Chemotherapy (Docetaxel) in Combination with Androgen Deprivation Therapy (ADT) for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC). Advances in Therapy, 2018, 35, 2186-2200.	2.9	7
15	A Patient-Centred Approach to Understanding the Trade-Offs Associated with Treatment Decision Making in Hematological Cancers with Short Life Expectancy. Blood, 2018, 132, 5899-5899.	1.4	O
16	Assessing the Comparability of Paper and Electronic Versions of the EORTC QOL Module for Head and Neck Cancer: A Qualitative Study. JMIR Cancer, 2017, 3, e7.	2.4	7
17	Assessing Asthma Symptoms in Adolescents and Adults: Qualitative Research Supporting Development of the Asthma Daily Symptom Diary. Value in Health, 2016, 19, 440-450.	0.3	25
18	The feasibility of using electronic clinical outcome assessments in people with schizophrenia and their informal caregivers. Patient Related Outcome Measures, 2015, 6, 91.	1.2	8

#	Article	IF	Citations
19	Assessing the Impact of Caring for a Person with Schizophrenia: Development of the Schizophrenia Caregiver Questionnaire. Patient, 2015, 8, 507-520.	2.7	18
20	The humanistic, economic and societal burden of Herpes Zoster in Europe: a critical review. BMC Public Health, 2015, 15, 193.	2.9	57
21	Unique Challenges in Development, Psychometric Evaluation, and Interpretation of Daily and Event Diaries as Endpoints in Clinical Trials. Therapeutic Innovation and Regulatory Science, 2015, 49, 813-821.	1.6	4
22	Development of a conceptual model evaluating the humanistic and economic burden of Crohn's disease: implications for patient-reported outcomes measurement and economic evaluation. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 643-656.	1.4	9
23	Burden of post-herpetic neuralgia in a sample of UK residents aged 50Âyears or older: findings from the zoster quality of life (ZQOL) study. Health and Quality of Life Outcomes, 2014, 12, 92.	2.4	40
24	"Sometimes It's Difficult to Have a Normal Life― Results from a Qualitative Study Exploring Caregiver Burden in Schizophrenia. Schizophrenia Research and Treatment, 2014, 2014, 1-13.	1.5	66
25	Burden of herpes zoster in the UK: findings from the zoster quality of life (ZQOL) study. BMC Infectious Diseases, 2014, 14, 402.	2.9	49
26	EVAPIL-R Scale: Continuous Development and Validation of a Tool to Assess Patient-Reported Tolerability of Different Contraceptive Methods in Longitudinal Studies. Clinical Therapeutics, 2014, 36, 638-647.e3.	2.5	4
27	Challenges in quantifying the patient-reported burden of herpes zoster and post-herpetic neuralgia in the UK: learnings from the Zoster Quality of Life (ZQOL) study. BMC Research Notes, 2013, 6, 486.	1.4	5
28	Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemia. Leukemia Research, 2012, 36, 817-825.	0.8	51
29	Haemophilia B: impact on patients and economic burden of disease. Thrombosis and Haemostasis, 2011, 106, 398-404.	3.4	54
30	An instrument assessing satisfaction with iron chelation therapy: Psychometric testing from an open-label clinical trial. Advances in Therapy, 2010, 27, 533-546.	2.9	11
31	Improved Patient Satisfaction, Adherence and Health-Related Quality of Life with Deferasirox (Exjade $\hat{A}^{\otimes}$ ) in $\hat{I}^2$ -Thalassemia Patients Previously Receiving Other Iron Chelation Therapies Blood, 2009, 114, 2486-2486.	1.4	4
32	Improved Health-Related Quality of Life in Patients with Hematological Disorders Receiving Deferasirox (Exjade®). Blood, 2008, 112, 1307-1307.	1.4	8